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(TKA). Multiple studies have confirmed the ability of tranexamic acid (TXA), an antifibrinolytic agent, to
effectively reduce blood loss and transfusion rates following TKA, without increasing the risk of
thromboembolic events. However, much controversy remains about the optimal regimen of TXA in primary
TKA. The purpose of this systematic review is to compare the safety and efficacy of topical TXA versus
intravenous (IV) TXA in primary TKA.
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intravenous TXA in primary, unilateral TKA were included. Analysis focused on specific outcomes including
total drain blood loss, postoperative hemoglobin (Hb) drop, frequency of transfusion, and thromboembolic
complications. The quality of evidence was assessed using a system known as the Grading of
Recommendations Assessment, Development, and Evaluation (GRADE).
Results: Of 194 papers identified, four trials were eligible for review. Analysis showed no significant
differences in total drain blood loss, postoperative Hb drop, frequency of transfusion, or thromboembolic
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Abstract   
 
Background: Perioperative blood loss is of major concern for patients undergoing a total knee 
arthroplasty (TKA). Multiple studies have confirmed the ability of tranexamic acid (TXA), an 
antifibrinolytic agent, to effectively reduce blood loss and transfusion rates following TKA, 
without increasing the risk of thromboembolic events. However, much controversy remains 
about the optimal regimen of TXA in primary TKA. The purpose of this systematic review is to 
compare the safety and efficacy of topical TXA versus intravenous (IV) TXA in primary TKA. 
 
Methods: An exhaustive literature search was performed using MEDLINE-Ovid, Web of 
Science, and Google Scholar. The following search terms were utilized: “total knee arthroplasty” 
OR “total knee replacement” AND “tranexamic acid.” All randomized studies comparing the 
effectiveness of topical versus intravenous TXA in primary, unilateral TKA were included. 
Analysis focused on specific outcomes including total drain blood loss, postoperative 
hemoglobin (Hb) drop, frequency of transfusion, and thromboembolic complications. The 
quality of evidence was assessed using a system known as the Grading of Recommendations 
Assessment, Development, and Evaluation (GRADE).  
 
Results: Of 194 papers identified, four trials were eligible for review. Analysis showed no 
significant differences in total drain blood loss, postoperative Hb drop, frequency of transfusion, 
or thromboembolic complications when comparing topical TXA and IV TXA in primary, 
unilateral TKA. 
 
Conclusion: The results of this review demonstrate that the topical administration of tranexamic 
has similar efficacy and safety profile to that of intravenous tranexamic acid in reducing blood 
loss and transfusion rates in primary TKA.  
 
Keywords: Tranexamic acid, topical, intra-articular, intravenous, total knee arthroplasty, total 
knee replacement 
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BACKGROUND 
Total knee arthroplasty (TKA) is one of the most common surgeries in orthopedics today. 
According to the American Academy of Orthopedics,1 most patients who undergo total knee 
replacement are age 50 to 80, with a diagnosis of osteoarthritis. There are no absolute restrictions 
in regards to medical history, age, or weight for TKA; however, studies2 have shown that at least 
85% of patients undergoing TKA have at least one comorbidity and 32.5% having three or more. 
Prior studies3 have also demonstrated increased surgical risk in the patient with multiple 
comorbidities.  Added surgical risk can lead to a higher probability of complications such as 
increased blood loss and transfusion rates, longer hospital stays, and poor functional outcomes. 
Perioperative blood loss is of major concern for patients undergoing a total knee 
arthroplasty (TKA) because of a large surgical incision, exposed trabecular bone, and activation 
of fibrinolysis.4 Previous studies5 have reported that estimated blood loss can vary between 1450 
to 1790 ml. The resulting blood loss anemia in patients can cause acute complications. In order 
to avoid such complications, patients are transfused. Blood transfusion rates in patients 
undergoing TKA have been reported to be between 11 to 21%.6 Blood transfusions can prove 
beneficial; however, they come with complications of their own such as surgical site infection, 
hemolysis, and immunosuppression.7,8 Given that side effects and complications are common 
after blood loss and transfusion, it is important to maintain hemodynamic stability in order to 
obtain fast recovery following TKA.  
In order to reduce the risks associated with blood loss and transfusion, other methods 
have been introduced to manage perioperative blood loss. One such method is the use of a 
synthetic antifibrinolytic agent called tranexamic acid (TXA). This pharmacologic agent is an 
analog of the amino acid lysine. TXA’s mechanism of action is to competitively inhibit 
plasminogen activation and plasmin binding to fibrin, resulting in a delay of fibrinolysis.9 TXA is 
not viewed as a procoagulant but more as a support for coagulation that is already in process.10 
Multiple studies have confirmed the ability of intravenous (IV) TXA to effectively reduce 
blood loss and transfusion rates following TKA, without increasing the risk of thromboembolic 
events.11,12 While IV TXA has been proven safe and effective, there is still concern that it could 
lead to thromboembolic events in a certain subset of patients, such as those with a history of 
recent stroke, angioplasty, or deep vein thrombosis (DVT). In consideration of these limitations, 
the topical use of TXA is another method that has been adopted to decrease perioperative blood 
loss. The effectiveness of topical TXA has also been proven to reduce peri-operative blood loss 
and transfusion rates without increased risk of thromboembolic events.13,14 When administered 
topically in the intra-articular space, TXA leads to 70% lower systemic absorption.13 In light of 
this, topical TXA may prove to be a good alternative to IV TXA; however, its safety and efficacy 
has only recently been compared to that of IV TXA. Can topical tranexamic acid (TXA) be as 
safe and effective as intravenous tranexamic acid in the reduction of blood loss in primary, 
unilateral total knee arthroplasty?  
METHODS 
An exhaustive literature search was performed using MEDLINE-Ovid, Web of Science, 
and Google Scholar. The following search terms were utilized: “total knee arthroplasty” OR 
“total knee replacement” AND “tranexamic acid.” The bibliographies of identified articles were 
searched for potential eligible reports. Inclusion and exclusion criteria were then applied. 
Inclusion criteria consisted of randomized studies, patients who underwent primary, 
unilateral total knee arthroplasty, intravenous tranexamic acid compared to topical or intra-
articular tranexamic acid, and reported outcomes including total blood loss, blood transfusion 
rates, and thromboembolic event rates. Additional inclusion criteria required studies in English, 
published within the last five years, and involving humans only. Studies were excluded if they if 
they addressed TXA therapy in additional orthopedic surgeries (such as total hip arthroplasty), or 
addressed other TXA methods of administration, beyond topical or IV. The quality of evidence 
was assessed using a system known as the Grading of Recommendations Assessment, 
Development, and Evaluation (GRADE). GRADE is a method used to assess the quality of 
evidence and decide whether to recommend an intervention.15 GRADE differs from other 
appraisal tools because it separates quality of evidence and strength of recommendation, the 
quality of evidence is assessed for each outcome, and studies can be ‘upgraded’ or ‘downgraded’ 
if they meet or fail to meet certain criteria. 
RESULTS 
In the initial search, there were 194 articles for review. After eliminating duplicates and 
screening for relevant articles using inclusion and exclusion criteria, there were a total of four 
relevant studies.16,17,18,19 Of the included studies, all were randomized, controlled studies in 
English and all were published after 2012.  
All participants in the study were adults, with mean ages ranging from 64.8 to 71.8. All 
patients were diagnosed with osteoarthritis (OA) and underwent primary, unilateral TKA (Table 
2). Doses of topical TXA ranged from 1.5 g to 3 g, all in 100 mL of normal saline (NS). Topical 
TXA was administered either topically as a TXA wash before closure of the surgical incision, or 
through a non-clamped drain during or immediately after closure. Doses of IV TXA ranged from 
1.5 g to 15 g, and were given in single-dose to triple-dose pre-op, intra-op, and post-op (Table 3).  
Gomez-Barrena et al 
This was a single-center, double-blind, randomized, controlled clinical trial16 that 
compared topical intra-articular TXA with two IV doses of TXA. The authors were looking at 
blood transfusion rate as their primary outcome. Secondary outcomes included but were not 
limited to blood loss (measured through a drain), change in hemoglobin (Hb) levels (pre-op to 
post-op), and thromboembolic events.16 
The authors started with all adult patients diagnosed with osteoarthritis who were 
scheduled to undergo primary, unilateral total knee replacement with cemented implants from 
January to October 2013 at La Paz Hospital in Cantoblanco, Madrid, Spain. Excluded from the 
study were patients who did not have written informed consent, allergy to TXA, major 
comorbidities, coagulopathy, history of arterial or venous thromboembolic disease, hematologic 
disorders, retinopathy, refusal of blood products, pregnancy, breastfeeding, or participation in 
another clinical trial during the last year.16 After meeting criteria, 78 patients were randomly 
allocated, 39 to an experimental group and 39 to a control group. A research statistician who 
used sequentially numbered opaque sealed envelopes, which were kept by research personnel 
until the day of surgery, organized group assignments. Envelopes were opened just prior to each 
surgery, and an uninvolved research anesthesiologist and pharmacist prepared the assigned study 
medication and placebo. Patients, surgeons, and health-care personnel involved in patient 
treatment and evaluation were blinded to group allocation throughout the entire study.16  
The average age of patients in the experimental group was 70.1, and 71.8 in the control 
group (Table 2). There were 26 female patients and 13 males in the experimental group. The 
control group consisted of 25 females and 14 males. There were no significant differences 
between the groups with respect to weight, height, body mass index, ASA (American Society of 
Anesthesiologists) status, preoperative lab results, or surgical characteristics.12  
The experimental group received a topical intra-articular dose of 3 g TXA in 100 ml 
saline (Table 3). Half of the volume was used to irrigate the surgical wound before closure, and 
the remaining half was administered intra-articularly through a drain tube after closure. The 
experimental group also received 100 ml of IV placebo saline solution 15 to 20 minutes before 
tourniquet release and 100 ml 3 hours later. Patients in the control group received an IV infusion 
of 100 ml of saline containing 15 mg/kg of TXA in the same aforementioned IV schedule. 
Additionally, the control group also received a topical intra-articular placebo.16  
Blood loss was measured through a drain at 3 and 24 hours. Postoperative hemoglobin 
level was measured at 24 hours, 48 hours, and approximately 5 days. While in the hospital, 
patients were examined daily for clinical suspicion of DVT, and a Doppler ultrasound was 
performed when there was clinical suspicion of DVT. Blood transfusion thresholds were set for 
patients with a hemoglobin level <8.0 g/dl who were asymptomatic, or <10.0 g/dl with 
symptoms.16  
No patients were lost or excluded during follow-up in this study. No transfusion was 
performed in either group (Table 4). Total drain blood loss in the experimental group and control 
group was 475.9 mL and 465.2 mL, respectively. Maximum post-operative hemoglobin drop was 
-3.4 in the experimental group, and -3.1 in the control group. No pulmonary embolism (PE) was 
noted in either group. Two patients in the experimental group had a clinical suspicion of DVT. 
One had a negative Doppler, and the other had Doppler confirmation of a superficial venous 
thrombosis, which was successfully treated with enoxaparin.16  
The authors of this study concluded that topical administration of TXA was not inferior 
to IV administration of TXA for patients undergoing primary TKA. They further assert that both 
regimens were equally safe and effective with respect to decreasing blood loss, blood transfusion 
rates, and thromboembolic events. The authors do recognize that their study lacked a placebo 
group, however; they note that the use of placebo would pose ethical issues regarding patient 
health and surgical success.16 
Patel et al 
This was a single center, single surgeon, prospective, randomized study17 that compared 
efficacy and safety profiles of IV versus topical TXA in patients undergoing primary, unilateral 
total knee arthroplasty within a nine month period. For a primary outcome, authors were most 
interested in the maximum difference between preoperative and postoperative hemoglobin. 
Secondary outcomes included but were not limited to: total drain output, frequency of 
transfusion, and rate of DVT or PE.17  
A total of 145 patients with a diagnosis of osteoarthritis underwent primary TKAs at the 
Jewish Hospital/Kentucky One Health, Louisville, KY. Of those patients, 100 consented to the 
study. Exclusion criteria for all patients included TKA for secondary osteoarthritis (eg, 
rheumatoid arthritis, gouty arthritis), simultaneous bilateral TKA, cardiovascular conditions, 
thromboembolic conditions, clotting disorders, religious objection to blood transfusion, 
preoperative hemoglobin >15.0 g/dl, allergy to TXA, and pregnancy.13 A total of 89 patients 
remained after criteria was applied, with 47 patients randomized to the topical group and 42 
patients to the IV group. Patients were randomized to their respective groups using Excel’s 
randomization generator. The surgeon and anesthesiologist were not blinded to the treatment 
groups due to the different routes of administration. However, postoperative nursing staff was 
blinded to group allocation.17 
The average age of patients in the topical group was 64.8, and 64.9 in the IV group 
(Table 2). The number of males and females in the topical group was 13 and 34, respectively. 
The IV group included 10 males and 32 females. There were no statistically significant 
differences between the two groups with regard to BMI, tourniquet time, or ASA status.17  
The IV TXA group received one IV 10 mg/kg dose of TXA 10 minutes prior to 
tourniquet release (Table 2). The topical group received 2.0 g TXA in 100 mL of normal saline, 
which was bathed in the surgical site and allowed to sit undisturbed for 2 minutes prior to 
tourniquet deflation. All patients received one deep and one superficial drain, and total drain 
outputs were measured on post-operative day (POD) 2. Postoperative hemoglobin was measured 
in morning of POD #1, 2, and 3, which were then compared to preoperative Hb. Guidelines for 
blood transfusion were patients with Hb <8 g/dl with symptoms. Patients were monitored daily 
for clinical suspicion of DVT/PE and received radiological studies if warranted.17  
No patients were lost or excluded during follow-up in this study. One patient in the 
topical group required blood transfusion (Table 3). The patient received preoperative clearance 
but was anemic prior to surgery with hemoglobin of 10.8. She was given 2 units of PRBCs on 
POD 3, after which time she experienced no further symptoms or complications. The total drain 
blood loss in the topical group was 630.2 mL and 558.7 mL in the IV group. Maximum Hb drop 
in the topical and IV group was -3.42 mg/dl and -3.06 mg/dl, respectively. There were no 
patients with DVT or PE, however; four patients in the IV group and two patients in the topical 
group received ultrasound (US) studies for DVT, which all showed negative results.17 
 The authors of this study concluded that topical administration of TXA has 
similar efficacy and safety profile to IV TXA in reducing blood loss following primary, 
unilateral TKA. The authors do recognize that their study failed to address functional outcomes 
of the two methods of administration. They also admitted that a longer follow-up period, beyond 
an average of 18.3 weeks, might be required to adequately compare the two groups.17  
Soni et al 
 This was a single surgeon, randomized study18 that compared the results of 
intravenous versus intra-articular, topical administration of TXA in perioperative blood loss in 
TKA surgery. The authors looked at total drain blood loss, maximum Hb drop from preoperative 
and postoperative lab values, frequency of transfusion, and incidence of DVT or PE.  
 A total of 80 patients with a diagnosis of osteoarthritis were scheduled to undergo 
primary TKA at a hospital in India. All 80 patients met eligibility criteria for the study. 
Exclusion criteria was as follows: known allergy to TXA, preoperative use of anticoagulants 
within 7 days, history or arterial or venous thromboembolic disease, fibrinolytic disorder, and 
renal or hepatic dysfunction. Patients were randomly divided into two groups. Group 1 contained 
40 patients who received IV TXA and group 2 contained 40 patients who received intra-articular 
TXA. Patients were randomly divided into these groups using computer derived random charts. 
There was no mention of blinding patients or staff in this study.18 
 The average age of patients was 69.05 in IV group and 69.45 in topical group 
(Table 2). The number of males and females in IV group was 19 and 21, respectively. There 
were 17 males and 23 females in topical group. There was no significant difference in pre-
operative Hb between the two groups.18  
 The intravenous group received three 10 mg/kg doses of TXA. The first dose was 
given 20 minutes before tourniquet was applied. The second dose was administered intra-
operatively and 15 min before deflation of the tourniquet, and the final dose was given 3 hours 
after the intra-operative dose (Table 3). For the topical group, 3 g of TXA diluted in 100 ml of 
normal saline was applied in the intra-articular space, after cementing of the implants and before 
tourniquet release. At least 5 minutes of contact was allowed. Postoperative protocol was the 
same for all patients. Total drain output was recorded at 48 hours; Hb was recorded after 48 
hours of surgery. Blood transfusion protocol was Hb <8 mg/dl. The authors state that patients 
were monitored for thromboembolic complications for 6 weeks postoperatively.18  
 There were no reports of patients lost to follow-up. Three patients in the IV group 
and four patients in the topical group received blood transfusions of 1 unit each. There were no 
adverse thromboembolic events reported in the study. Total drain blood loss in the IV group was 
409.50 ml and 386.50 ml in the topical group (Table 4). Maximum Hb fall in the IV group was -
2.42 mg/dl and -2.21 mg/dl in the topical group.18   
 The authors reported that there was no significant difference in Hb fall, blood 
drain output, transfusion rates, or safety profiles between the two groups. They concluded that 
intra-articular TXA is as effective as three doses of IV TXA in preventing blood loss during 
TKA. The authors admit that they did not screen for thromboembolic events in their study but 
state that clinically they did not observe any symptoms among their patient groups. They also 
believe that their sample size is small and that a larger study is indicated to yield more thorough 
and applicable results.18 
 
 
Seo et al 
This was a prospective, randomized, placebo controlled study19 designed to determine if 
topical or IV administration of TXA is more effective in controlling hemodynamic stability after 
TKA. Outcome measures included but were not limited to blood loss during surgery, difference 
between preoperative and postoperative hemoglobin levels, frequency of transfusion, and 
complications of DVT or PE.  
 A total of 150 patients between the ages of 55 and 80 years old with diagnoses of 
osteoarthritis underwent TKAs at hospitals in South Korea. All 150 patients met eligibility 
criteria for the study. Exclusion criteria was patients with any cardiovascular problems, 
cerebrovascular accident (CVA) conditions, thromboembolic disorders, or those showing a 
deteriorating disorder.19 Fifty patients were randomly allocated to the IV group, 50 patients to the 
intra-articular group, and 50 patients to the placebo group. Patients were allocated to each group 
using a random number list. There is no mention of blinding patients or staff in this study.19  
 The average age of patients in the IV group was 66.8 and 67.5 in the intra-
articular group (Table 2). The number of males and females in the topical group was 5 and 45 
respectively. There were 6 males and 44 females in the IV group. There was no significant 
difference in BMI, preoperative flexion/contraction, skin incision, or operation time between the 
two groups.19  
 Patients in the IV group received 1.5 g of TXA in 100 ml of saline, which was 
administered immediately following closure of surgical site. The intra-articular group received 
1.5 g TXA in 100 ml of saline injected directly into the joint cavity while suturing (Table 3). All 
patients received two intra-articular drains, which were removed at 24 hours after the drainage 
amount was recorded. Hb levels were recorded preoperatively and postoperatively, and the 
greatest Hb was calculated. Blood transfusion protocol was set at <8 g/dl or <10 g/dl with 
symptoms.19  
 There were no reports of patients lost to follow-up. Ten patients in the topical 
group and 17 in the IV group required postoperative transfusions (Table 4). The average amount 
of transfused PRBCs in the topical and intravenous group was 129.6 ml and 273.6 ml, 
respectively. There were three reported cases of DVT in the topical group and none in the IV 
group. All patients with DVT were treated and experienced no further complications. Total drain 
blood loss was not recorded in this study. Maximum Hb fall in the topical group was -1.8 and -
1.6 in the IV group.19  
 Of note are study results for the placebo group, who received an equal volume of 
100 ml normal saline intravenously, as well as a 100 ml of saline directly into the knee joint 
cavity while suturing. Results for the placebo group included a maximum Hb fall of 2.0 mg/dl. 
Forty-seven placebo patients received blood transfusions; averaging 920.8 ml of PRBCs. Mean 
blood loss for the placebo group during surgery was 833 ml, compared to 528 ml and 426 ml in 
the intravenous and intra-articular groups respectively.  
 The authors of this study concluded that the intra-articular injection of TXA 
seemed to be more effective than IV injection in reducing blood loss and transfusion frequency 
in patients undergoing TKA. The authors admit that their study, while large, still lacked enough 
patients to prove statistical significance. They further admit that all patients in their study 
underwent TKA using extramedullary alignment technique by a single surgeon thus, it would be 
impossible to compare the findings in this study with those who used a more conventional TKA 
approach. The authors also recognize that there was no formal observation or recording of 
patient symptoms or recovery beyond the observational time frame of this study. 
DISCUSSION 
Tranexamic acid, an antifibrinolytic drug, has been routinely used to prevent 
perioperative bleeding in patients undergoing TKA. The effectiveness of IV TXA in orthopedic 
surgery has been well researched. 5,11 However, there remains concern regarding the systemic 
absorption and sequelae of IV TXA. Intra-articular application of TXA is considered to be a 
safer method of administration because it works directly at the surgical site and systemic 
absorption is not as significant.13 Thus, the question addressed in this review is if topical TXA is 
as safe and effective as IV TXA in controlling blood loss in patients undergoing TKA. 
Analysis of four randomized clinical trials16,17,18,19 showed no significant differences in 
total drain blood loss, postoperative Hb drop, frequency of transfusion, or thromboembolic 
complications when comparing topical TXA and IV TXA in primary, unilateral TKA (Table 4). 
In regards to total drain blood loss, there were three of four studies16,17,18 that reported on this 
outcome. In two of the studies16,17 the IV groups showed slightly less volume loss, ranging 
between 71.5 and 10.7 ml when compared to topical groups. Maximum postoperative Hb drop in 
three of the studies16,17,19 favored the IV groups, but only by a difference of 0.2 to 0.36 mg/dl. 
Interestingly, when comparing all four studies,16,17,18,19 there were four more patients in the IV 
groups who received blood transfusions when compared to topical groups. Lastly, while DVT 
and PE were uncommon across all studies, there were three reported DVTs among patients in the 
topical group of Seo et al.19 However, it should be mentioned that there was uncertainty 
surrounding DVT and PE screening in all four studies.16,17,18,19 All four studies evaluated patients 
with clinical symptoms of DVT and PE, and provided no screening for asymptomatic patients. 
Therefore, it is difficult to draw an accurate conclusion in regards to the thromboembolic events. 
  It seems that the observed outcomes discussed above do not reach the level of major 
clinical importance. As such, topical TXA could be a good option for patients at higher risk for 
thromboembolic events, or patients where IV TXA use is cautioned or contraindicated.  
There were limitations of the studies reviewed. Firstly, the quality of each study differs. 
Soni et al18 and Seo et al19 were lower quality randomized trials, due to lack of information on 
blinding of participants and personnel. The remaining two studies16,17 were moderate-to-high 
quality. Secondly, not all reporting was standardized across the four trials,16,17,18,19 making it 
difficult to accurately compare data points. As a result, this review was limited to four common 
outcomes, when there were in fact many other outcomes of interest. Third, further studies should 
include functional outcomes data. While follow-up was substantial for the outcomes of interest, 
there was a lack of relevant data in regards to quality of life post TKA. Finally, all four 
trials16,17,18,19 excluded high-risk patients, such as those with cardiac history or history of 
thromboembolic events. Given the fact that the average age of TKA patients is 50 to 80 years old 
with comorbidities, the results and conclusions listed here should be used taken with caution in 
clinical practice. Medical providers should continue to evaluate each patient individually for 
contraindications to the use of TXA.  
Worth noting are the role of placebo groups in these four clinical trials. Seo et al19 
implemented a placebo group in their study design, and the results compared to both the IV and 
TXA groups are significant. Forty-seven of the 50 patients in the placebo group received blood 
transfusions, compared to 10 patients in the topical group and 17 in the IV group. Furthermore, 
mean blood loss during surgery was approximately 300 ml more than either the topical or IV 
groups. Gomez-Barrena et al16 chose not to add a placebo group to their study based on ethical 
issues that have been raised as a result of prior TXA studies.20 These studies illustrated the 
likelihood of increased risk of transfusion among patients in the placebo arm.  
It is advised that future studies not include a placebo group due to the unethical nature of 
placing patients at risk of increased blood loss and transfusion rates. Secondly, future studies 
should include patients with significant comorbidities, or those who are considered high risk so 
that the safety profile of TXA can be more accurately defined. Thirdly, functional outcomes and 
quality of life should be measured. By incorporating a longer follow-up period, the lasting effects 
of TXA administration, both IV and topical, could be delineated. Future studies also need a more 
consistent and reliable method to screen patients for DVT or PE, beyond the use of clinical 
suspicion. Finally, a shared drawback in regards to fully assessing safety of topical TXA of all 
four of the studies16,17,18,19 discussed above was their small sample size. Studies with more 
patients and improved methods are needed to conclusively define the optimal regimen of TXA in 
primary TKA.  
CONCLUSION  
In conclusion, the results of this review demonstrate that the topical administration of 
tranexamic has similar efficacy and safety profile to that of intravenous tranexamic acid in 
reducing blood loss during total knee arthroplasty. With respect to avoiding blood transfusions, 
both regimens were equally efficacious and safe. Additionally, both regimens equally controlled 
blood loss, without complications. Considering topical TXA works directly at the surgical site 
and has markedly decreased systemic absorption, topical application could be a more rational 
choice. Medical providers may want to choose the topical route of administration for patients 
who are poor candidates for intravenous TXA, such as those with renal insufficiency, history of 
previous DVT, and cebrovascular and cardiac disease.  
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   Table 1: Quality Assessment of Four Reviewed Studies 
 
Outcome 
Number 
of 
studies 
Study 
Designs 
Downgrade Criteria 
Upgrade 
Criteria 
Quality 
Limitations Indirectness Inconsistency Imprecision 
Publication 
bias 
Total Drain 
Output 
3 RCT, 
cohort 
Seriousa Not Serious Not Serious Not Serious Unlikely None Moderate 
Max 
Hemoglobin 
Drop 
4 RCT, 
cohort 
Seriousa Not Serious Not Serious Not Serious Unlikely None Moderate 
Blood Units 
Transfused 
4 RCT, 
cohort 
Seriousa Not Serious Not Serious Not Serious Unlikely None Moderate 
Thromboembolic 
Events 
4 RCT, 
cohort 
Seriousa Not Serious Not Serious Seriousb Unlikely None Low 
aLack of blinding  
bSmall sample size 
Table 2: General Characteristics of Four Reviewed Studies 
 
Studies Year of 
Publication 
Number of Patients Country Patient Age Unilat 
primary 
TKA 
Gender FU Study 
design 
  Topical IV  Topical IV  Topical IV   
Gomez-
Barrena, E 
2014 39 39 
 
Spain 70.1 71.8 All M: 13 
F: 26 
M: 14 
F: 25 
4 RCT 
Patel JN 2014 
 
47 42 USA 64.8 64.9 All M: 13 
F: 34 
M: 10 
F: 32 
4.6 mos RCT 
Soni A 2014 
 
40 40 India 69.45 69.05 All M: 17 
F: 23 
M: 19 
F: 21 
1.5 mos RCT 
Seo JG 2013 50 50 South 
Korea 
67.5 66.8 All M: 5 
F: 45 
M: 6 
F: 44 
2 mos RCT 
Table 3: General Surgical Information of Four Reviewed Studies 
 
Studies Intervention Technique Pneumatic 
Tourniquet 
Transfusion 
Protocol 
 Topical IV Topical IV Topical & 
IV 
Topical & 
IV 
Gomez-Barrena, E 3 g/100mL NS Two doses of 15 
mg/kg 
Half topical before 
closure, half admin 
through drain 
during closure 
One dose intra-op 
and one dose post-
op 
Yes 
 
Hb<8.0 g/dL  
OR  
Hb<10 g/dL + 
sxs 
Patel 2 g 
TXA/100mL 
NS 
One dose of 
10mg/kg 
2 min topical before 
tourniquet release, 
with drain 
 
One dose intra-op Yes 
 
Hb<8.0 g/dL + 
sxs 
Soni A 3 g 
TXA/100mL 
NS 
3doses of 
10mg/kg  
1.5g TXA; IA 
injected through 
drain after closure 
One dose PO, IO, 
PO 
Yes 
 
Hb<8.0 g/dL 
Seo JG 1.5g 
TXA/100mL/
NS 
1.5 g 
TXA/100mL NS 
IA while suturing 
w/non-clamp drain 
One dose post-op Yes 
 
Hb<8.0 g/dL  
OR  
Hb<10 g/dL + 
sxs 
 
 Table 4: Summary of Findings 
Studies Number of pts Total Drain Blood 
Loss (ml) 
Max Postop Hb 
Drop (mg/dl) 
Number of 
patients who 
received post-op 
blood transfusion 
DVT PE 
 
 
 Topical IV Topical IV Topical IV Topical IV Topical IV Topical IV 
Gomez-
Barrena, E 
39 39 475.9 
 
465.2 
 
-3.40 
 
-3.10 
 
0 0 0 0 0 0 
Patel 47 42 630.2 
 
558.7 -3.42 -3.06 1 0 0 0 0 0 
Soni A 40 40 386.50 409.50 -2.21 -2.42 
 
4 3 0 0 0 0 
Seo JG 50 50 - - -1.8 -1.6 
 
10 17 3 0 0 0 
